New Lac-Phe Compounds with Better Absorption for Treating Metabolic Syndrome

Compound 18 demonstrated superior metabolic stability and pronounced appetite suppression compared to Lac-Phe.

• Lac-Phe, an exercise-induced metabolite, shows poor appetite suppression when taken orally due to low metabolic stability.
• A comprehensive analysis led to the identification of compound 18, which improves appetite control and metabolic stability.
• Compound 18 inhibits two receptors associated with fat cravings, GPR40 and GPR120.
• The compound alleviates obesity and fatty liver by affecting a specific signaling pathway involved in metabolism.
• These findings suggest potential for compound 18 in developing new treatments for metabolic syndrome.

Simplified